Background Junctional epidermolysis bullosa (JEB), a group of hereditary skin fragility
INTRODUCTION
JEB is genetically and clinically heterogeneous, but in all forms trauma-induced tissue separation occurs at the level of the lamina lucida of the dermal-epidermal basement membrane [1] . The mostly lethal JEB-Herlitz is caused by null mutations in the LAMA3, LAMB3, or LAMC2 genes encoding laminin polypeptides and JEB with pyloric atresia by mutations in the integrin genes ITGB4 and ITGA6. A phenotypically variable group, coined JEB-other, is associated with missense mutations in the above laminin genes or with mutations in COL17A1 encoding collagen XVII [2] . The COL17A1 phenotypes exhibit a wide range of severity and, in addition to skin blistering, different degrees of mucosal involvement, enamel defects, dystrophy or loss of nails, and alopecia can occur. The causes for the phenotypic variability are not well understood. Although more than 60 COL17A1 mutations have been reported in the literature (http://www.hgmd.cf.ac.uk/ac/index.php), the only clear genotype-phenotype correlation is that patients with complete lack of collagen XVII in the skin exhibit severe, generalized blistering with mucosal and adnexal involvement, whereas patients with reduced amounts of normal or with mutated collagen XVII in the skin display more moderate symptoms [3, 4] .
The COL17A1 gene (NM_000494.3) on chromosome 10q24.3 comprises 56 exons [5] . proteinases, yielding a shorter form of the protein which remains stable in the extracellular matrix [6] . Thus, functionally, collagen XVII plays a dual role as a cell surface receptor and as a matrix component. During steady-state homeostasis, it maintains adhesion of basal keratinocytes to the basement membrane. Shedding of the ectodomain releases the cell from some of its binding partners and allows it to become motile during epidermal differentiation or during wound healing and tissue regeneration [7] .
Recent pilot studies on causal therapies for genetic skin diseases have shown that relatively small biological changes, e.g. moderately increased levels of a missing protein in the skin, can have substantial clinical effects [8] . Specifically, fibroblast-based cell therapies of collagen VII-deficient dystrophic epidermolysis bullosa demonstrated that about 35 % of physiological levels of the collagen confer greatly improved skin integrity [9, 10] and, in a human pilot trial, gene therapy for JEB partially restored laminin 332 in the skin and significantly ameliorated the phenotype [11] . This was corroborated by a recently described laminin gamma-2 hypomorphic mouse [12] , which has low levels of laminin 332 in the skin and a moderate phenotype, in contrast to the perinatally lethal laminin 332 knockout mice [13, 14, 15] . These observations suggest that the multiprotein complexes at the dermalepidermal junction are highly stable with robust interactions of the binding partners, which can compensate a significant, but not complete, loss of one component. On this background, we addressed the role in skin integrity of a major component of the epidermal adhesion complex, collagen XVII, in a large cohort of patients with collagen XVII-deficient JEB.
PATIENTS AND METHODS

Patients and tissue samples
Forty-three patients of Caucasian ancestry and European origin were investigated. They were suspected to have EB and presented at the Freiburg EB-center for clinical evaluation and diagnosis, or DNA and skin samples were provided by collaborating centers. Following informed consent, EDTA-blood and skin samples were obtained from the patients and, if available, from family members. The study was approved by the ethics committee of the University of Freiburg.
Immunofluorescence staining
Immunofluorescence staining of the skin was performed using a panel of antibodies to components of the epidermal basement membrane zone as described [16] . For diagnostic purposes, the following domain-specific collagen XVII antibodies were used: the polyclonal antibody NC16A, which binds to the NC16A domain of collagen XVII, and the monoclonal NC16A1 recognizing amino acids 513-525 [17, 18, 19] . 
Keratinocyte cultures
Primary epidermal keratinocytes were isolated from skin biopsies of patients 28, 38 and 15
and of a normal control, and cultivated in keratinocyte growth medium (Invitrogen, Karlsruhe, Germany), as described [21] . They were used for RNA and protein isolation in passage 2 at 80% confluence.
Mutation detection and RNA analysis
Genomic DNA (gDNA) was extracted from EDTA-blood using the QiAmp DNA mini kit (Qiagen, Hilden, Germany). For amplification of all COL17A1 exons and exon/intron boundaries primers were used as described [5, 22] , and sequencing was performed on an ABI 7330XL DNA analyzer. Mutations were confirmed by resequencing in both directions. 5'-ctgtgctcatggaagagctg, amplicon of 633bp; exon 51F 5'-gctgaaaacagcgacagctt and exon 54R 5'-gtcacgttgctgtaggcaga with a product of 532bp. The PCR products were separated on 1.5% agarose gels. The RT-PCR products were subcloned to TOPO TAcloning vector (Invitrogen, Karlsruhe, Germany), and for each reaction, 10 to 15 clones were sequenced using the M13-RV primer.
Immunoblotting
For immunoblotting, cultured keratinocytes were extracted with a buffer containing 0.1 M NaCl, 20 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, Pefabloc and EDTA [18, 23] . Protein content was quantified with a micro Lowry assay (DC Protein Assay, Bio-Rad, Munich, Germany).
Normalized amounts of the proteins were subjected to SDS-PAGE, immunoblotted and incubated with the following anti-collagen XVII polyclonal antibodies: ecto-4, recognizing epitopes within the 50 most C-terminal amino acids and NC16A [18, 24, 25] . The blots were 
RESULTS
Mutation detection strategy and novel COL17A1 mutations
Forty-three European patients with JEB-other were included in this study (Table 1) . Most mutations were located in exons 51 and 52. Notably, splice-site mutations occurred preferentially in intron 51. Using this approach, the mutation detection rate reached 98.8 % (85/86 alleles). Thirty-four distinct mutations were disclosed, suggesting that most families have their own private mutation ( Figure 1 ). The majority, 69%, were nonsense mutations, insertions and deletions predicted to lead to a premature termination codon (PTC).
Missense mutations comprised 19%, and splice-site mutations 12% of the survey. The mutations were distributed over the entire COL17A1 gene ( Figure 1 ). Two mutations were found to be recurrent in European patients. The non-population-specific mutation p.Arg1226X [3, 4, 26] was found in almost 10%, and p.Gly803X [27] in approximately 7% of the mutated alleles.
Phenotypic variability
To assess disease severity the following clinical parameters were recorded during multiple patient visits: extent of skin and mucosal involvement, nail dystrophy and alopecia. Twentyseven of the 43 patients had a disseminated blistering and a generalized disease phenotype [28] , whereas 11 had a localized phenotype. No clinical data was available of five patients. All patients had dystrophic toe nails and the only patients with normal finger nails were 28, 35 and 36. For almost half of the patients, dental anomalies were reported, including enamel defects and subsequent susceptibility to caries and/or parodontitis [29] .
On molecular level, the individuals with severe clinical phenotypes were homozygous or compound heterozygous for PTC or splice-site mutations and exhibited the full spectrum of symptoms: generalized blisters, alopecia and nail anomalies [1, 30] ( Intriguing was the constellation observed in patients 28, 35, 36 and 38 with minimal, localized blistering and toe nail dystrophy ( Figure 2D -H). They had had mild traumainduced blistering since childhood, but only sought medical attention when age-related health conditions aggravated the blistering. This was first misinterpreted as an acquired bullous disease, but recalcitrance to therapies finally led to the diagnosis of JEB at the advanced age of 67 -80 years.
In order to explain the phenotypic variability, we focused on biological consequences of splice site mutations, which are delineated in the following.
Splice-site mutations associated with mild phenotypes in elderly individuals
The 80 year-old patient 28 presented with blisters mostly on the gluteal area and the thighs, as she was restricted to bed because of joint problems, and with toe nail dystrophy In contrast to the mutations described above, the outcome of the novel splice-site mutation c.3766+5G>A, at the donor splice site of exon 51 was associated with a severe phenotype in the 1 year-old patient 15. He suffered from congenital and persisting generalized blistering, mucosal involvement and nail dystrophy. In accordance, three of the four transcripts representing more than 80% of the clones, resulted in frame-shift and PTC. One minor transcript could not be identified in the analyzed clones. Only transcript 4 (18% of the clones) led to in-frame skipping of exon 51. This deletion is predicted to encompass amino acids 1207-1255 and to eliminate the NC5, COL5 and NC6 domains of the protein ( Figure   5 ). However, the truncated collagen XVII was obviously unstable and susceptible to degradation, since neither immunofluorescence staining of the skin (not shown) nor immunoblotting of keratinocyte extracts revealed presence of collagen XVII protein ( Figure   5 ).
DISCUSSION
Here we describe genotype-phenotype correlations in a cohort of 43 European JEB patients with collagen XVII mutations. The group exhibited a wide spectrum of clinical variability ranging from mild, predominantly acral blistering to severe phenotypes with generalized blistering, mucosal involvement, extensive nail dystrophy and universal alopecia. In general, the milder pathological manifestations were associated with missense or splice-site mutations and the presence of at least some collagen XVII in the skin. The hallmark of the severe phenotypes was total lack of collagen XVII in the skin, but different mutation mechanisms were found to underlie the deficiency. Delineation of such mechanisms is a pivotal for understanding the molecular pathology and a prerequisite for development of novel, biologically valid therapies.
Particularly interesting was the observation that splice-site mutations allowing low expression of collagen XVII generate mild disease manifestations, as has been suggested in individual case reports [31, 32] . Illustrative examples of this were the elderly patients 28, 35, 36 and 38, who had had very few symptoms during past several decades. Occasional skin fragility had been suspected to represent an acquired condition. However, with advancing age, diseases such as diabetes or increasing physical immobility aggravated the blistering, and the patients were finally diagnosed with JEB in their 7 th or 9 th decade of life. These observations suggest that comorbidities are modifying factors of JEB and should alert medical professionals to critically re-evaluate individuals suspected to have an acquired skin blistering disorder, which does not respond to therapy.
Based on the data in the present study, we predict that both the percentage of transcripts not causing PTCs and the location of the splice-site mutation play a role in the outcome on protein level. All splice-site mutations described here targeted collagenous subdomains of the collagen XVII molecule. Some, but not all of them had devastating effects on the stability of collagen XVII and led to degradation of unstable molecules by tissue proteinases. Mutations within collagenous domains are known to perturb the G-X-Y repeat motif and affect the stability of the ectodomain, leading to unfolding and degradation of the collagen XVII molecule [25, 33, 34] . Biochemical analyses of transcripts and mutant polypeptides, as performed here, may become useful prognostic markers for determining the course of the disease at an early stage and be helpful for counselling the patients relating to genetic and environmental contributions to their disease and quality of life. As reported for other EB forms, modifying factors might influence the phenotype [35, 36] . Our results suggest that environmental conditions related to physical activity and trauma, as well as comorbidities are aggravating circumstances. Modifier genes and epigenetic factors are certainly involved in modulation of phenotypic variations. In the case of missense and truncating mutations, misfolded proteins are subjected to intracellular degradation, processes which are likely to be subject of inter-individual variations [37] .
In terms of therapeutic perspectives, an important finding in this study is that already a low percentage of functional collagen XVII translated from the transcripts of splice-site mutations can confer a mild skin phenotype, in contrast to the null variants. The natural history of JEB in four aged individuals with 2-4% of collagen XVII in vitro and about 12 -14 % of normal collagen XVII levels in vivo demonstrated that for successful biological therapies it will not be necessary to achieve 100 % restoration of collagen XVII in the skin, but already smaller increases will improve dermal-epidermal stability and alleviate symptoms in JEB. 
